Twitter Facebook LinkedIn

News & Events

February 8, 2022 | Shionogi – SIDERO-WT

SIDERO-WT Program
Conducted by Shionogi
Active: 2014-2019

Countries Canada, Czech Republic, France, Germany, Greece, Hungary, Italy, Russia, Spain, Sweden, Turkey, UK, USA

Primary objective
Annual evaluation of cefiderocol activities against US/EU Gram-negative isolates. To evaluate the antibacterial activity of cefiderocol and comparators against a wide variety of Gram-negative bacteria including carbapenem-resistant isolates.

 

Protocol SummarySIDERO-WT, antibiotic susceptibility surveillance data for each isolate from North America and Europe in 2014 to 2019. In five consecutive annual SIDERO-WT surveillance studies (2014 to 2019), the susceptibility of cefiderocol and comparators against Gram-negative clinical isolates from North America and Europe was evaluated by broth microdilution. MICs of cefiderocol have been determined by broth microdilution assay using iron-depleted cation-adjusted Mueller-Hinton broth, which has been approved by CLSI and EUCAST. MICs of other comparators have been determined by broth microdilution assay using cation-adjusted Mueller-Hinton broth, which has been approved by CLSI and EUCAST. The breakpoints of comparators were based on published information by CLSI and EUCAST.
47615 isolates (including 31,896 isolates of Enterobacterales, 7,700 isolates of Pseudomonas aeruginosa, 5,225 isolates of Acinetobacter baumannii complex, 2,030 isolates of Stenotrophomonas maltophilia, and 425 isolates of Burkholderia cepacia complex).
Isolates collection methodPredefined quotas of isolates of specific Gram-negative bacilli cultured from patients with intra-abdominal, urinary tract, lower respiratory tract, skin and soft tissue, or bloodstream infections were collected from clinical laboratories in North America and Europe from November 2014 to December 2019.

For methods: http://aac.asm.org/content/61/9/e00093-17.full.pdf+html?sid=d0d5821d-867f-48f9-8037-4e6cc05ab717. For QC ranges: http://www.dmidjournal.com/article/S0732-8893(17)30105-0/abstract
Types of surveillanceRoutine clinical practice then used for surveillance.
Number of Isolates47615
Contains pediatric data?No
Contains genotype data?No
Date Last Updated31-Dec-2019
Expected frequency of updates to the datasetSIDERO-WT completed in 2019, other surveillance studies (SENTRY by JMI) started from 2020, which is available on JMI SENTRY website https://mvp.jmilabs.com/
Dataset FormatExcel
List of publications to be linked https://doi.org/10.1128/AAC.01990-21
https://doi.org/10.1016/j.ijantimicag.2018.11.007
https://doi.org/10.1128/AAC.00093-17
Any additional informationMIC concentration abbreviations: 0.0019=≤0.002, 0.0299 = ≤0.03, 0.0599= ≤0.06, 0.1199= ≤0.12,0.2499= ≤0.25, 1.999= ≤2, 4.0001= >4, 8.0001= >8, 16.0001= >16, 32.0001= >32, 64.0001=>64, 256.0001=>256
Annual data is published as separate studies. New surveillance data is not integrated with the previous surveillance data.